Direct answer: should I have bariatric surgery to control my blood pressure?

For most patients with obesity and hypertension that requires multiple medications, yes. The GATEWAY randomized trial 5-year results published in JACC in February 2024 showed 86.5% of bariatric surgery patients reduced their antihypertensive medications by at least 30% while maintaining controlled blood pressure, compared to 12.5% with medical therapy alone. About half achieve full remission at 1 year. Roughly 30% maintain remission at 5 to 7 years.

The most striking finding: at 5 years, 0% of surgery patients met criteria for apparent resistant hypertension, compared to 15.2% on medical therapy alone.

My short rule is this:

• BMI above 35 with hypertension on 2 or more medications: strong indication.
• Apparent resistant hypertension on 4 or more medications plus obesity: surgery is one of the strongest interventions we have.
• Mild hypertension on 1 medication, BMI 30-35: GLP-1 or lifestyle first, surgery if it progresses.

The 30-second summary

In February 2024, the Journal of the American College of Cardiology published the 5-year results of the GATEWAY trial, the only randomized controlled trial designed specifically to test bariatric surgery against medical therapy for hypertension in patients with obesity. At 5 years, 86.5% of the gastric bypass group had reduced their antihypertensive medications by at least 30% while maintaining controlled blood pressure, compared to 12.5% in the medical therapy group. The chance of hypertension remission was nearly 20 times higher in the surgical group. Zero percent of surgery patients met criteria for apparent resistant hypertension at 5 years, compared to 15.2% on medical therapy alone. Combined with the STAMPEDE 5-year data and the long-term SOS mortality findings, the picture is clear: in patients with obesity and hypertension, bariatric surgery beats medication on every metric that matters. Here is what that actually means for you.

Why I treat high blood pressure as a surgical disease

Hypertension is the leading single risk factor for cardiovascular death worldwide. In the United States, more adults die each year from complications of high blood pressure than from any other modifiable risk factor. Among my patients with severe obesity, almost two thirds have measurable hypertension by the time they reach my office. About one in four are on three or more medications. A meaningful subset is on four or more and still not controlled. That last group has resistant hypertension, and they are the patients I want to see most.

Here is what is happening underneath.

Excess visceral fat drives systemic inflammation. Adipose tissue releases angiotensinogen, aldosterone, and inflammatory cytokines that activate the renin-angiotensin-aldosterone system. Your sympathetic nervous system runs hotter than it should. Your kidneys retain more sodium than they should. Your arterial walls stiffen. You take a pill that works against one part of that cascade, then another pill that works against another part, and at some point you are on five medications and your blood pressure is still 145 over 95 in the office.

This is not your willpower failing. This is the biology of obesity-driven hypertension. The pills are working against the disease without addressing what is causing it. Lose 25 to 30% of your body weight and most of that physiology reverses. Your renin-angiotensin axis quiets down. Your sympathetic output drops. Your sodium handling normalizes. The medications you needed before become unnecessary.

That is the mechanism. The GATEWAY trial is the proof.

The GATEWAY trial: the first RCT specifically for hypertension

For decades, the bariatric literature on hypertension was secondary data. Observational cohorts and trials designed for diabetes that mentioned blood pressure in passing. Then in 2017 Carlos Schiavon and colleagues in São Paulo enrolled 100 patients with hypertension (defined as requiring 2 or more medications at maximum doses, or 3 or more at moderate doses) and BMI between 30 and 39.9. They randomized them 1:1 to Roux-en-Y gastric bypass plus medical therapy or medical therapy alone.

The 1-year results, published in Circulation in 2018, were striking. 83.7% of the surgery group achieved the primary endpoint (≥30% reduction in antihypertensive medications while maintaining BP below 140/90) compared to 12.8% of the medical group. 51% of surgery patients reached complete hypertension remission.

The 5-year follow-up published in JACC in February 2024 confirmed durability. 86.5% of the surgery group maintained the medication reduction, compared to 12.5% in the medical group. The hazard ratio for hypertension remission favored surgery by approximately 20-fold. And perhaps most importantly, zero percent of the surgery group met criteria for apparent resistant hypertension at 5 years, compared to 15.2% of the medical therapy group.

Note the population. These were not severely diabetic patients. The majority did not have diabetes. They were people who carry obesity and have blood pressure that does not respond to maximum medical therapy. That is a description of millions of adults in the United States and Latin America right now.

What actually happens to your blood pressure after a gastric sleeve

Although GATEWAY tested gastric bypass specifically, my practice and the published literature on the sleeve show similar effects with a slightly different curve.

First 4 to 8 weeks. Blood pressure starts dropping almost immediately. The pre-op two-week liquid diet alone usually produces a 5 to 10 mmHg drop. Post-op, as visceral fat begins to dissolve and your insulin sensitivity restores, the renin-angiotensin axis quiets. Many patients tell me by week 6 that they feel light-headed in the morning on their usual medications. That is not a complication. That is your old medication regimen being too aggressive for your new physiology. We start titrating down.

Months 3 to 6. Maximum medication adjustment happens here. By month 6, most of my patients are on half their previous medication burden, sometimes less. Patients on five medications routinely drop to two or three. Patients on three drop to one or zero.

Months 6 to 12. Maximum weight loss with the Enhanced Gastric Sleeve happens around month 12. By that point, most patients have reached their new BP equilibrium. This is when we check whether full discontinuation is appropriate.

Years 1 through 5. This is the durability question. The GATEWAY 5-year data shows the benefit is real. A separate retrospective cohort study found that among patients who initially achieved hypertension remission after surgery, the relapse rate at 5 years was 54%. That sounds high until you compare it to the relapse rate in non-surgical controls who somehow lost enough weight to remit: 78%. Surgical remission is more durable, but it is not permanent for everyone. Long-term BP monitoring matters.

Can I stop my blood pressure medications after surgery?

Maybe. The published data is encouraging but the decision is yours and your cardiologist’s, not mine, and not based on how you feel.

Here is the protocol I use with my patients:

Week 4 post-op: home BP log daily, morning and evening. Cardiologist or PCP review.
Week 6 to 8: first medication titration down, usually beta-blocker or diuretic first.
Month 3: second titration if BP remains stable below 130/80.
Month 6: third titration if applicable.
Month 12: full review with cardiologist on whether to discontinue any remaining medications.
After: home BP cuff weekly indefinitely.

The mistake I see most often in patients post-bariatric is feeling great and stopping all medications on their own. Blood pressure is asymptomatic until it is not. You can have BP of 165 over 100 and feel fine, while your kidneys and arteries take damage in the background. The whole point of doing this surgery is to reduce your cardiovascular risk. Stopping medications without data does not reduce risk. It just removes the safety net.

What about Ozempic, Mounjaro, or other GLP-1s for blood pressure?

I am asked this often. The honest comparison.

Semaglutide (Ozempic, Wegovy) reduces systolic blood pressure by approximately 4.8 mmHg on average across meta-analyses. Tirzepatide (Mounjaro, Zepbound) reduces it by approximately 7 mmHg. Both are meaningful reductions, particularly because they appear to be mediated by weight loss. The European Heart Journal individual patient meta-analysis from 2024 confirmed that essentially all of the BP benefit from semaglutide is mediated by weight reduction.

Compare that to bariatric surgery, where systolic BP reductions of 15 to 30 mmHg are common in the GATEWAY cohort, and remission rates approach 50% at 1 year.

Same conversation we have for any chronic medication. GLP-1s work for the duration you take them. The cost is significant if not insurance-covered. Most patients regain the weight and lose the BP benefit within 12 months of stopping. We do not yet have 10-year cardiovascular outcome data for GLP-1s in the way we have it for surgery (SOS, Adams cohort, Aminian cohorts).

For mild-to-moderate hypertension in patients who are not surgical candidates, a GLP-1 is a reasonable choice. For severe or resistant hypertension in a patient with BMI above 35, the published evidence continues to favor surgery.

Who should not expect full hypertension remission

Surgery is not magic. The patients least likely to achieve full hypertension remission include:

• Patients with longstanding hypertension (more than 10 to 15 years). The vascular damage is too established.
• Patients over 60. Age-related arterial stiffness is harder to reverse.
• Patients with kidney disease (CKD stage 3 or worse). The renal contribution to BP regulation is impaired and may not respond to weight loss alone.
• Patients with anatomical contributors like primary aldosteronism, pheochromocytoma, or renal artery stenosis. These are secondary hypertensions and need separate workup.
• Patients who regain significant weight in the first 2 to 3 years post-op.

For these patients, surgery still helps. They will need fewer medications. Their BP will be more controlled. But full discontinuation may not be the right goal. The right goal becomes "lower cardiovascular risk with fewer pills," not "off all medications."

What the Enhanced Gastric Sleeve specifically does for hypertension patients

In my practice, every hypertensive patient who comes through for the Enhanced Gastric Sleeve gets a few specific protocols.

Pre-op cardiology clearance with echocardiogram if BP has been poorly controlled or there is any concern about left ventricular hypertrophy. Medication optimization the week before surgery to ensure BP is controlled at induction. Intraoperative arterial line for continuous BP monitoring in high-risk cases. Post-op, gradual reintroduction of antihypertensive medications based on actual BP readings rather than habit. Coordination with the patient’s cardiologist or PCP in their home country for ongoing management.

The technique itself, the Enhanced Gastric Sleeve with double buttress staple line reinforcement and drain-free protocol, contributes by minimizing operative stress and getting patients walking the same day. Mobility matters for cardiovascular recovery in this population.

Quick answers

Will bariatric surgery cure my high blood pressure?
The GATEWAY 5-year trial showed 86.5% of surgery patients reduced their medications by at least 30% while maintaining controlled BP, vs 12.5% with medical therapy. About half achieve full remission at 1 year. Approximately 30% maintain remission at 5 to 7 years.

How long after surgery does my BP improve?
Within 4 to 8 weeks. Maximum benefit at 12 months, coinciding with maximum weight loss.

Can I stop my BP medications after gastric sleeve?
Maybe, but only with data and in coordination with your cardiologist or PCP. We titrate stepwise based on home BP readings.

Does bariatric surgery reduce my heart attack risk?
Yes. SOS study: 30.7% reduction in all-cause mortality. MOSAIC study (in OSA patients): 42% reduction in cardiac events.

Can my BP come back after surgery?
Yes, 54% relapse at 5 years among initial remitters. We monitor long-term.

Is GATEWAY only about gastric bypass?
GATEWAY used Roux-en-Y gastric bypass. STAMPEDE included both bypass and sleeve and showed similar BP medication reductions. Observational sleeve data consistently shows benefit.

What about resistant hypertension on 4+ medications?
Strong indication for surgery. GATEWAY 5-year: 0% of surgery patients met resistant hypertension criteria at 5 years vs 15.2% medical.

Can Ozempic or Mounjaro lower my BP?
Yes, but less. Semaglutide ~4.8 mmHg SBP reduction, tirzepatide ~7 mmHg. Bariatric surgery: 15 to 30 mmHg in GATEWAY cohort.

What to do next

If you have hypertension and you carry significant obesity, especially if you are on 3 or more medications, or if your blood pressure is still not controlled despite maximum medical therapy, the next step is a virtual consultation. I will review your medication list, your home BP readings if you have them, your echocardiogram if recent, and your overall metabolic picture. We will talk about whether surgery makes sense for you compared to continuing to add medications, and what your post-operative BP management plan would look like.

You can request a free virtual evaluation, and my coordinator Lucia will reach out to schedule.

Hypertension is the leading single cause of cardiovascular death. Bariatric surgery, in the GATEWAY 5-year data, beat every alternative we currently have for patients with obesity and difficult-to-control blood pressure. You have options that medication alone will not give you.

For the complete picture of how bariatric surgery affects all major obesity-related conditions, including procedure-specific differences and honest comparisons with GLP-1 medications across each condition, see the comprehensive evidence guide.

Sources

1. Schiavon CA, Cavalcanti AB, Oliveira JD, et al. Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years. J Am Coll Cardiol. 2024;83(5):637-648. PMID: 38325988
2. Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132-1142. PMID: 29133606
3. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes – 5-Year Outcomes (STAMPEDE). N Engl J Med. 2017;376(7):641-651. PMID: 28199805
4. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219-234. PMID: 23163728
5. Remission and Relapse of Hypertension After Bariatric Surgery: A Retrospective Study on Long-Term Outcomes. PMC10013161
6. Kennedy C, Hayes P, Salama S, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J. 2024;45(38):4124-4134.
7. Aminian A, Wang L, Al Jabri A, et al. Adverse Cardiovascular Outcomes in Patients With Obstructive Sleep Apnea and Obesity: Metabolic Surgery vs Usual Care (MOSAIC). J Am Coll Cardiol. 2024;84(7):589-602.
8. Eisenberg D, Shikora SA, Aarts E, et al. 2022 ASMBS and IFSO: indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356.

---

Authored by Dr. Gabriela Rodríguez Ruiz, MD, PhD, FACS. Updated based on the GATEWAY 5-year results (JACC, February 2024), the STAMPEDE 5-year follow-up (NEJM 2017), and the latest meta-analyses comparing GLP-1 receptor agonists to surgical weight loss for blood pressure outcomes.